ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
24 announcements with these filters
Lyka Labs Limited submitted a revised press release for Q1 FY27 results to correct typographical errors. The company reported a consolidated net profit of Rs. 2.05 Crore.
Lyka Labs Limited conducted its 47th Annual General Meeting on August 10, 2026. Shareholders transacted business including the adoption of financial statements and approval of related party transactions.
Lyka Labs Limited reported its Q1 FY27 results with consolidated net total income of Rs. 42.73 Crore. Standalone net profit surged 159% year-on-year to Rs. 2.10 Crore.
Lyka Labs Ltd reported revenue from operations of ₹42.3 Cr (+28.2% YoY) and net profit of ₹2 Cr (+100.0% YoY) for Q1 FY27.
Lyka Labs Ltd scheduled a board meeting for August 10, 2026. The meeting will consider the Q1 unaudited financial results.
Lyka Labs allotted 462,711 equity shares following an NCLT-approved amalgamation with Lyka Exports, as disclosed in this quarterly shareholding pattern filing.
Lyka Labs issued a notice for its 47th AGM scheduled for August 10, 2026. Key agendas include approving Rs. 75 Crore in related party transactions.
Lyka Labs submitted its 47th Annual Report for FY 2025-26. The Annual General Meeting is scheduled for August 10, 2026, via video conferencing.
Lyka Labs convened its 47th AGM for August 10, 2026. Agenda includes approving a Rs. 75 Crore related party transaction limit with IPCA Laboratories.
Promoter Kunal Gandhi and related parties bought 55,967 shares on the open market. Their stake now equals 16.19% of Lyka Labs.
Promoter Kunal Gandhi acquired 6,533 shares via open market for ₹0.46 Crore. Another acquisition of 5,000 shares was reported for Alisha Gandhi.
Lyka Labs allotted 4,62,711 equity shares to shareholders of Lyka Exports under a sanctioned scheme. This completes the amalgamation and increases paid-up capital to Rs.36.15 Crore.
Lyka Labs Ltd clarified to BSE that no material event caused the recent price movement. The company confirms all required disclosures are up to date.
Lyka Labs received a favorable NCLAT order to recover ₹0.63 Crore from Modi Life Care Industries Limited. The payment must be received within thirty days.
Lyka Labs Ltd reported revenue from operations of ₹28 Cr (-16.2% YoY) and a net loss of ₹8.1 Cr for Q4 FY26.
Lyka Labs reported audited FY26 results alongside a ₹23.01 Crore impairment on its subsidiary investment. Net loss widened significantly due to this exceptional charge.
Lyka Labs scheduled a board meeting for May 25, 2026, to approve audited financial results. The meeting will cover both standalone and consolidated annual figures.
Lyka Labs Limited declared that it does not fall under the 'Large Corporate' category as of March 31, 2026, per SEBI guidelines. Consequently, the mandatory requirement for incremental borrowing through debt securities is not applicable. The company reported outstanding long-term borrowings of Rs. 20.15 Crore and maintains a BBB+ credit rating.
Lyka Labs Limited announced that India Ratings & Research Pvt. Ltd. has affirmed its credit rating for ₹33.28 Crore (INR 332.8 million) in bank facilities. The long-term rating is IND BBB+/Stable and the short-term rating is IND A2.
Lyka Labs Limited announced that its merger with Lyka Exports Limited became effective on April 8, 2026, following NCLT approval. The Appointed Date is April 1, 2022. Consequently, the company's authorized share capital automatically increased to ₹59 Crore. This consolidation aims to streamline group operations and corporate structure.
Lyka Labs Limited clarified to BSE that there is no material information or event requiring disclosure under SEBI Regulations that could impact recent share price movements. The company maintains its commitment to regular dissemination of relevant information to the exchanges.
Lyka Labs Limited clarified to the NSE that there is no undisclosed material information or event impacting the recent significant movement in its share price. The company confirmed it remains in compliance with SEBI listing regulations and continues to disseminate all relevant information regularly.
Lyka Labs Ltd reported a net loss of ₹0.2 Cr for Q3 FY26.
Lyka Labs Limited has submitted the compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations for the quarter ended March 31, 2026. The certificate, issued by MUFG Intime India Private Limited, confirms the processing of dematerialisation requests within prescribed timelines.